



# Caféine et HTA: bon ou mauvais?

Dr B Ponte, Msc


Médecin adjointe agrégée, CC

Service de Néphrologie – Hôpitaux Universitaires de Genève

# PLAN

---

- Un peu d'histoire et d'épidémiologie
- Caféine: métabolisme
- Caféine et santé?
- Caféine et HTA ?
- Conclusions



A close-up photograph of several dark brown, roasted coffee beans, showing their characteristic shape and texture. The beans are piled together, with some in sharp focus and others blurred in the background.

# Caféine: Histoire et description

---

Histoire du café commence déjà 800 AD....

- 1819: Isolation de la caféine par physicien allemand (Friedlieb Ferdinand Runge)
- 1821: description de la caféine (Pelletier et Robiquet)
- 1827: Isolation théine du thé (Oudry)
- 1838: démonstration que théine = même substance que caféine.
- Fin du XIXème siècle, élucidation de la structure de la caféine (Hermann Emil Fischer) .

## TEA, COFFEE, AND COCOA.

ON Wednesday Mr. Ernest Hart, Chairman of the Council of the National Health Society, delivered an address on this subject at the rooms of the Society, 53, Berners Street, in which he aimed at dispelling many common errors, and discussing the matter in hand practically as well as from the scientific point of view. The lecturer began by referring to the overwhelming argument in favour of these beverages deducible from the principle *quod ubique, quod ab omnibus*. A universal, discriminating, and all-powerful instinct had led first all the nations of the East and the South to use as their beverage, and subsequently all the Western nations, to adopt from them beverages derived from tea, coffee, Paraguay tea, cocoa, Guarana chocolate, or the kola nut. These were all extremely different in their flavour, and altogether different in their sources of origin. The tea was the dried leaf of a camellia; coffee the dried seed of a species of cinchona; the Paraguay tea, drunk by millions of people in Southern America, was derived from the leaves of a holly; guarana from the seed of paullinia; kola from the nut of sterculia. Modern chemical processes had succeeded in discovering that the whole of these beverages were characterised, however different in flavour or source, by the presence of a single and practically identical alkaloid or active principle known as theine or caffeine. Taking tea and coffee as the two typical beverages of the kind prevalent throughout the East and in Western Europe, Mr. Ernest Hart proceeded to discuss what were the important matters known or unknown about them, and to compare the methods of preparation and of infusion which prevailed in the West and in the East. Describing in comparative detail the processes of plucking and preparing China tea and the teas of India and Ceylon, he pointed out that however different in detail, they were essentially alike in principle. After plucking from the shrub the leaf was subjected to the softening and wrinkling process known as withering; the leaves were then, in India, China, and Ceylon, fermented in a wet mass, rolled and crushed under heavy pressure, re-roasted and packed for the market. In Japan the practice differed especially for teas intended for home consumption. The leaf was moistened by steam, roasted at a very mild heat or basket fired, rolled, and for the purposes of the finest tea reduced to powder, which was the most highly esteemed and the only kind of tea used in the tea ceremonies of Japan. It will be observed that the essential point in all these modes of preparation is the *softening* of the tealeaf and the *crushing* it so as to set free within the substance of the leaf the theine and essential oils which it contains, so as to render them more easily diffused when infused in hot water as a beverage. In all cases the leaf most highly valued was the small top leaf of the twig and the bud. There was no reason whatever, however, to believe that this was either finer in quality, richer in content, or intrinsically better in flavour than the leaves next in succession, but being more tender and softer in structure, it yielded more completely to the crushing process and gave better and more flavoured liquor.

Setting aside for the moment the various obscure and untrustworthy varieties of preparation and selection of China tea, as to which there was much mystery and some misrepresentation, and dealing only with Indian, Ceylon, and Japan teas, where everything was open and above board, Mr. Hart pointed out that the common and prevalent impression that the trade names Orange Pekoe, Pekoe, Suchong, Congou, represented different products having some generic distinction, was altogether unfounded and contrary to the fact. They were all the same in respect of origin; they were picked at the same time from the same plant and from the same bush. The bud and the top leaf constituted Orange Pekoe, the two or three larger leaves growing on the same twig a little lower down were Suchong, and below that the leaves became Congou, a name, however, not much recognised either in Indian or Ceylon teas.

After describing the mode of growth and of selection of the leaf, the lecturer paid a warm compliment to the Ceylon teas and the Indian teas, pointing out, however, that the great favour with which Ceylon teas were now regarded was no doubt due to the fact that, while equally rich in theine, they had a less proportion of tannin than the Indian teas. In

1880 the total export of tea from Ceylon was under 130,000 lbs.; this year it had reached 80,000,000 lbs. The housewife, in selecting a fine tea, should not be guided by any trade name, but should obtain Orange Pekoe of whatever growth, whether from Ceylon, Assam, or Darjeeling, and should then determine by pouring a little boiling water over the leaves, and examining them that the leaf was a whole leaf, and not cut into small pieces from the larger leaf, as was commonly the practice. The larger the leaf the weaker the infusion and the less the value. Green tea from China was for the most part tea fermented and made bitter like black tea, and then faced with Prussian blue or indigo to simulate green tea. Nearly all the Indian and Ceylon teas were also fermented and were all black teas.

The only true natural green tea produced in quantity by any country now was the green tea of Japan as drunk by the natives and largely consumed in America. This tea was neither so bitter nor so strong as to require to be doctored with an albuminoid fluid such as milk to make it drinkable, or with sugar to further hide its bitterness. It needed to be infused only for a short time, never more than five minutes, and the water used should be just off the boiling point, so as not to dissipate the delicate aroma of the tea. Japanese "green," or unfermented and unfaced tea, so drunk was, in the lecturer's opinion, the very perfection of the beverage. Our European tastes, however, had so long been vitiated by the habit of drinking the strong, bitter, fermented tea, that he had no great anticipation that any but the more delicate and cultivated palate would appreciate and habitually prefer this exquisitely aromatic and harmless beverage, which was the staple drink of the far East. He showed the mode of preparing tea after the fashion of the Japanese from a series of specimens, some of his own importation, and some procured from a Japanese resident in London.

Referring then to the question of tannin in tea, Mr. Hart gave the result of a series of experiment, which threw much doubt upon the current views on the subject. It was supposed generally that letting the hot water stand upon the leaves more than fifteen minutes extracted a considerable additional amount of tannin from the tea, and was very deleterious. This was hardly the fact. After fifteen minutes very little more tannin could be extracted from the tea by the ordinary methods of infusion. What came over was an unpleasant disagreeably flavoured bitter extractive, which had lost all delicacy of flavour, and was unpleasant to the palate, but it did not contain the excess of tannin popularly attributed to it. Tannin was so highly soluble that it was dissolved in the water from the very first instant of contact, and the three minutes' infusion of pale tea contained a very large proportion of tannin. He agreed with Sir William Roberts in believing that the alleged ill-effects of the tannin in the tea were probably very much exaggerated, and that the ill-effect of drinking too much tea and too strong tea were due to the theine and volatile extractives of the tea, and not to the tannin. It was quite a fallacy to suppose, although he often saw it stated, that common teas contained more tannin than the choicer varieties. In many cases the opposite was the fact. Varieties of tea, however, such as the "digestive" tea, might be had in which the tannin of the tea was so altered by electrical treatment that it did not precipitate gelatine, and interfered but little with the digestion of starch; of these Mr. Hart showed specimens which he considered deserving of notice.

The most essential point of all for making good tea of the finest quality, and with the least waste, was the thorough crushing of the leaf, and its subdivision in such a manner that the largest possible surface was rapidly exposed to the boiling water in infusing it. Hence the traditional preference by the Japanese, who in this matter had shown their customary intelligence and refinement of taste, for their carefully prepared and selected "tea powder," which produced the finest tea in the world. Hence, too, probably, the superiority of the thoroughly crushed tea bricks of the best quality formerly sent from China to Russia. This matter had been greatly overlooked in the West, but undoubtedly it was the key to any further progress in the art and economics of tea drinking. The difficulties and disadvantages of tea powder obtainable in Europe at present were its liability to adulteration, its uncertain mixture, and the discomforts attending



# Café-ine consommation

---


## USA

- 75% adultes boivent café
- 50% quotidiennement
- 2011: 4.24kg/an par tête
- Consommation moyenne =200-300mg/h

## CH

- 7.85kg/an par tête

# Café-ine consommation




| Subgroup               | Adjusted mean coffee intake, fluid ounces/d |                     |            |            |            |            |
|------------------------|---|---------------------|------------|------------|------------|------------|
|                        | Overall (2003–2012)                         | NHANES survey cycle |            |            |            |            |
|                        |   | 2003–2004           | 2005–2006  | 2007–2008  | 2009–2010  | 2011–2012  |
| Overall                | 11.4 ± 0.3                                  | 11.8 ± 0.6          | 11.8 ± 0.4 | 11.1 ± 0.5 | 11.6 ± 0.5 | 10.8 ± 0.4 |
| Sex                    |   |                     |            |            |            |            |
| Female                 | 10.0 ± 0.2                                  | 10.1 ± 0.4          | 10.2 ± 0.5 | 9.8 ± 0.5  | 10.2 ± 0.4 | 9.6 ± 0.4  |
| Male                   | 12.9 ± 0.4                                  | 13.7 ± 0.9          | 13.6 ± 0.5 | 12.4 ± 0.7 | 13.0 ± 0.8 | 12.1 ± 0.8 |
| Age                    |   |                     |            |            |            |            |
| 20 to <30 y            | 4.8 ± 0.3                                   | 4.5 ± 0.5           | 4.0 ± 0.6  | 4.9 ± 0.7  | 5.8 ± 0.6  | 4.7 ± 0.7  |
| 30 to <40 y            | 9.5 ± 0.4                                   | 10.0 ± 0.7          | 10.0 ± 0.7 | 8.7 ± 0.9  | 9.9 ± 1.0  | 9.1 ± 0.5  |
| 40 to <50 y            | 13.4 ± 0.5                                  | 14.9 ± 1.3          | 14.5 ± 0.9 | 12.5 ± 0.7 | 13.1 ± 0.9 | 12.0 ± 1.1 |
| 50 to <60 y            | 15.0 ± 0.6                                  | 15.2 ± 1.4          | 16.6 ± 1.2 | 15.1 ± 1.6 | 15.6 ± 0.8 | 13.0 ± 0.6 |
| ≥60 y                  | 13.6 ± 0.4                                  | 13.9 ± 0.6          | 13.6 ± 0.6 | 13.5 ± 0.9 | 13.0 ± 0.5 | 14.1 ± 1.0 |
| Race/ethnicity         |   |                     |            |            |            |            |
| Non-Hispanic black     | 4.9 ± 0.2                                   | 5.3 ± 0.5           | 5.3 ± 0.5  | 4.4 ± 0.4  | 4.6 ± 0.3  | 4.8 ± 0.4  |
| Hispanic or other race | 8.5 ± 0.3                                   | 8.9 ± 0.5           | 9.8 ± 0.5  | 8.0 ± 0.5  | 7.8 ± 0.5  | 8.3 ± 0.5  |
| Non-Hispanic white     | 13.2 ± 0.3                                  | 13.6 ± 0.6          | 13.5 ± 0.5 | 12.9 ± 0.6 | 13.7 ± 0.6 | 12.4 ± 0.5 |



# Autres substances dans le café

- ✓ Magnesium
- ✓ Polyphenols flavanoides....
- ✓ Diterpenes
- ✓ melanoidins

## LIGNANI



↓TC and LDL-C levels<sup>[161,162]</sup>, ↓incidence of diabetes<sup>[7]</sup>, ↓inflammatory molecules<sup>[163]</sup>, ↑FMD<sup>[163]</sup>, decrease in atrial fibrillation in patients at high risk for CVD<sup>[169]</sup>.

## OTHERS POLYPHENOLS


**Curcumin:** ↓TC, LDL-C, TG and ↑HDL-C<sup>[178]</sup>.

**Silymarin:** ↓TC, LDL-C and TG<sup>[176-177]</sup>.

**Triterpenes:** Improve the lipoprotein particle subclasses distribution and their associated atherogenic ratios<sup>[171]</sup>, HDL-C efflux capacity significantly improved<sup>[172]</sup>, ↑HDL size, promoted a greater HDL stability and enhanced the HDL oxidative status<sup>[173,174]</sup>, ↓cIMT<sup>[170]</sup>.


## FLAVONOIDS

### FLAVONOLS




Significant ↓TC, LDL-C, TG, ↑HDL-C<sup>[95,96,93,100]</sup>, significant ↓LDL oxidizability<sup>[99]</sup>, ↓insulin<sup>[96]</sup>, lowers BP<sup>[95,96]</sup>, ↓WC and hip circumference<sup>[100]</sup>, weak risk reduction for CHD death with a higher intake<sup>[102]</sup>, LDL lipid hydroperoxide content was not increased by myricetin, nor did it promote the depletion of the endogenous antioxidant alpha-tocopherol in the LDL<sup>[103]</sup>, protects against lipid peroxidation, reduces VCAM-1 and E-selectin<sup>[45]</sup>, positive effect on hypertension<sup>[44,47]</sup>, reverse endothelial vasomotor dysfunction<sup>[44,48,49]</sup>.

### FLAVONES




Beneficial effect on plaque progression<sup>[74]</sup>, inhibited collagen- and arachidonic acid-induced platelet aggregation in washed human platelets, inhibited the phosphorylation of PLCγ2, PKC, MAPKs in collagen-activated human platelets, and markedly ↓intracellular calcium mobilization and OH formation<sup>[51]</sup>, did not affect either phorbol-12,13-dibutyrate-stimulated PKC activation or platelet aggregation, neither SQ22536, an adenylate cyclase inhibitor nor 1H-[1,2,4]oxadiazol[4,3-a]quinoxalin-1-one significantly reversed<sup>[51]</sup>, inhibits the platelet-derived growth factor-induced proliferation and migration of smooth muscle cells<sup>[42]</sup>.

### ISOFLAVONES




↓LDL-C<sup>[57]</sup>, ↓DBP<sup>[56]</sup> and improve postprandial microvascular endothelial reactivity<sup>[77]</sup>, ↓cIMT progression<sup>[3,8,9,129]</sup>, ↓cIMT progression<sup>[3,8,9,129]</sup>, ↓TC, LDL-C and TG<sup>[61,65]</sup>, ↓risk of ischaemic stroke and risk of MI<sup>[4]</sup>.

### FLAVANONES




Beneficial effect on plaque progression<sup>[74]</sup>, significantly modified lipids, LDL subclasses and cIMT<sup>[68]</sup>.

### ANTHOCYANIDINS



↓TC, TG and LDL-C<sup>[81,82,111,112,23]</sup>, ↑HDL-C concentration<sup>[81,84]</sup>, ↓CETP<sup>[85]</sup>, ↑blood glucose<sup>[84,124]</sup>, ↓insulin<sup>[17]</sup>, ↓serum malondialdehyde, urinary 8-OHdG and isoprostanes levels<sup>[82,87,81]</sup>, ↓oxidative stress<sup>[82,86,112]</sup>, blocking anti-death signaling mediated via JNK-1 and c-JUN<sup>[106]</sup>, ↓SBP and DBP<sup>[87]</sup>, ↓J15,116,117,118,121,122, ↓BMI<sup>[96,118]</sup>, ↓platelet aggregation, increase platelet-derived NO release and decrease superoxide production<sup>[96,118,126,127]</sup>, ↓cIMT<sup>[125,126]</sup>, improved brachial artery FMD and digital pulse amplitude tonometry<sup>[81,112,114,116,117,118]</sup>, not associated with MI or total stroke risk<sup>[80,81]</sup>.


### FLAVANOLS



Significant ↓TC, LDL-C, TG, ↑HDL-C<sup>[95,96,93,100]</sup>, significant ↓LDL oxidizability<sup>[99]</sup>, ↓insulin<sup>[96]</sup>, lowers BP<sup>[95,96]</sup>, ↓WC and hip circumference<sup>[100]</sup>.


## PHENOLIC ACIDS

### CINNAMIC ACID




↓fasting glucose<sup>[139,142]</sup>, ↓TC, TG, LDL-C, non HDL-C<sup>[139,140]</sup>, lower risk of diabetes<sup>[142]</sup>, ↓SBP and arterial elasticity<sup>[143]</sup>, ↓BMI and abdominal fat<sup>[143]</sup>, lower risk of CVD<sup>[142,143]</sup>, inhibition of LDL oxidative modification<sup>[144]</sup>, ↑IL-6<sup>[143]</sup>.

### BENZOIC ACID



Improved brachial artery FMD<sup>[133]</sup>, acute glycaemic control of actions<sup>[134,135]</sup>.

### STILBENES



Improvement of FMD<sup>[147]</sup>, ↓lipid profile (LDL-C, ApoB, oxLDL/ApoB ratio), ↑non-HDL-C (total atherogenic cholesterol/ApoB ratio)<sup>[88]</sup>, significant ↓markers of inflammation (TNF-α, PAI-1, IL-6, IL-10 ratio, and sICAM), and ↑IL-10 and adiponectin ↓oxidative stress<sup>[148,156,158,159]</sup> ↓fibrinolytic biomarkers<sup>[148]</sup>, ↑anti-inflammatory serum adiponectin and ↓thrombogenic PAI-1<sup>[155]</sup>, positive effect on inflammatory markers<sup>[150]</sup>, protection against cardiovascular or cerebrovascular disease<sup>[151,157]</sup>, enhance FMD acutely<sup>[153]</sup>, mRNAs regulation<sup>[156]</sup>.

# Caféine contenue dans...


Estimated caffeine content of commonly consumed beverages.

| Beverage                      | Caffeine (g) | Volume (mL) |
|-------------------------------|--------------|-------------|
| Cup of hot chocolate          | 10 mg        | 250 mL      |
| Arizona green iced tea        | 15 mg        | 470 mL      |
| Arizona black iced tea        | 32 mg        | 470 mL      |
| Can of Coca Cola              | 32 mg        | 375 mL      |
| Cup of Lipton green tea       | 35 mg        | 150 mL      |
| Cup of Lipton black tea       | 55 mg        | 150 mL      |
| Starbucks Café Latte – short  | 75 mg        | 236 mL      |
| Red Bull Energy drink         | 80 mg        | 250 mL      |
| Iced coffee                   | 99 mg        | 500 mL      |
| Espresso shot                 | 106 mg       | 25 mL       |
| Starbucks Café Latte – grande | 150 mg       | 473 mL      |
| Monster Energy drink          | 160 mg       | 473 mL      |
| Wired X344 Energy drink       | 344 mg       | 473 mL      |
| Fixx Energy drink             | 500 mg       | 591 mL      |

# Caféine: métabolisme

« 1, 3, 7 – triméthylxanthine » = purine alcaloïde

- Métabolisme hépatique : 95% CYP1A2




Ratio paraxanthine/caféine informe sur activité CYP1A2




# CYP1A2: métabolisme et génétique

- Facteurs génétiques expliquent variation métabolisme caffeine
- CYP1A2 variants → ↓ PA non fumeurs  
→ ↑ prise caffeine
- CYP1A2 activity → ↓ PA




# Mesure: Questionnaire café vs dosage



|                           | Sensitivity | Specificity | Cutoff (mg) |
|---------------------------|-------------|-------------|-------------|
| 24-h urinary metabolite   |             |             |             |
| 24-h urinary caffeine     | 0.723       | 0.840       | 1.391       |
| 24-h urinary paraxanthine | 0.801       | 0.790       | 2.582       |
| 24-h urinary theophylline | 0.787       | 0.800       | 0.774       |
| 24-h urinary theobromine  | 0.938       | 0.160       | 1.665       |

# Café-ine: Effets sur la santé ?

## CAFFEINE



- Phosphodiesterase inhibition → ↑cAMP
- Adenosine (A<sub>1</sub>R, A<sub>2</sub>A) receptor inhibition
- Norepinephrine release from sympathetic nerve endings
- Inhibition of Ca<sup>2+</sup> reuptake into SR → ↑ intracellular Ca<sup>2+</sup>
- Increased myofilament Ca<sup>2+</sup> sensitivity



## ACUTE

Inhibition of adenosine-induced hyperemia → ↓myocardial perfusion\*

↑ Inotropy

↑ automaticity → pro-arrhythmia\*  
↑ triggered activity


Rise in blood pressure

Increased aortic stiffness

## CORONARY ARTERIES



## MYOCARDIUM



## SYSTEMIC CIRCULATION



## CHRONIC

Reduced coronary artery disease

Reduced T2DM incidence


Reduced heart failure

Improved heart rate variability

Reduced atrial fibrillation


No significant effect on blood pressure

Reduction in ischemic stroke





| Outcome                                       | No of events /total | Follow-up range (years) | Risk estimate (95% CI) | Estimate (95% CI)     | Total studies | Cohort | Case-control | $\tau^2$ | $I^2$ (%) | Egger's P value | AMSTAR |
|---|---------------------|-------------------------|------------------------|-----------------------|---------------|--------|--------------|----------|-----------|-----------------|--------|
| <b>10 most harmful</b>                        |                     |                         |                        |                       |               |        |              |          |           |                 |        |
| Acute leukaemia in childhood <sup>88,89</sup> | NP                  | NA                      |                        | 1.44*† (1.07 to 1.92) | 3             | 0      | 3            | NP       | 42        | 0.33            | 4      |
| Lymphoma <sup>60</sup>                        | 219/124 131         | NP                      |                        | 1.29 (0.92 to 1.80)   | 3             | 3      | 0            | 0.04     | 18        | ND              | 7      |
| Lung cancer <sup>47</sup>                     | 11 145/NP           | NP                      |                        | 1.28 (1.12 to 1.47)   | 8             | 8      | 0            | 0.02     | 87        | ND              | 5      |
| Urinary tract cancer <sup>49</sup>            | NP                  | NP                      |                        | 1.18* (1.01 to 1.38)  | 14            | 0      | 14           | NP       | NP        | 0.51            | 6      |
| Endometriosis <sup>81</sup>                   | 387/385             | NP                      |                        | 1.13 (0.46 to 2.76)   | 3             | 1      | 2            | 0.43     | 70        | ND              | 5      |
| Hypertension <sup>35</sup>                    | 36 178/1 246 388    | 6-33                    |                        | 1.03 (0.98 to 1.08)   | 4             | 4      | 0            | 0.00     | 73        | ND              | 6      |
| Gastric cancer <sup>50</sup>                  | 1535/255 112        | 2-25                    |                        | 1.02 (0.79 to 1.31)   | 8             | 8      | 0            | 0.07     | 58        | ND              | 7      |
| Rectal cancer <sup>52</sup>                   | 4594/NP             | NA                      |                        | 0.98* (0.85 to 1.13)  | 10            | 0      | 10           | NP       | 71        | NP              | 4      |
| Breast cancer <sup>38</sup>                   | NP‡                 | 8-24                    |                        | 0.95 (0.90 to 1.01)   | 11            | 11     | 0            | 0.00     | 20        | 0.58            | 5      |
| Venous thromboembolism <sup>33</sup>          | 4215/65 951         | 12-19                   |                        | 0.94 (0.82 to 1.07)   | 2             | 2      | 0            | 0        | 0         | ND              | 3      |
| <b>10 most beneficial</b>                     |                     |                         |                        |                       |               |        |              |          |           |                 |        |
| Colorectal cancer <sup>52</sup>               | 9568/NP             | NA                      |                        | 0.83* (0.73 to 0.95)  | 13            | 0      | 13           | NP       | 80        | NP              | 4      |
| Urinary incontinence <sup>68</sup>            | 7284/47 518         | NP                      |                        | 0.75* (0.54 to 1.04)  | 3§            | 1      | 0            | 0.08     | 93        | ND              | 6      |
| Alzheimer's disease <sup>127</sup>            | 454/5497            | NP                      |                        | 0.73 (0.54 to 0.99)   | 2             | 2      | 0            | 0.00     | 0         | ND              | 3      |
| Liver fibrosis <sup>63</sup>                  | 1414/3738           | NP                      |                        | 0.73* (0.56 to 0.94)  | 7             | 7      | 0            | 0.08     | 81        | ND              | 7      |
| Chronic kidney disease <sup>69</sup>          | NP/14 898           | NA                      |                        | 0.71 (0.47 to 1.08)   | 4§            | 0      | 0            | 0.11     | 66        | ND              | 7      |
| NAFLD <sup>62</sup>                           | NP/2407             | NP                      |                        | 0.71 (0.60 to 0.85)   | 3§            | 1      | 1            | 0        | 0         | ND              | 7      |
| Liver cancer <sup>43</sup>                    | 3414/2 267 143      | 10-44                   |                        | 0.66 (0.55 to 0.78)   | 12            | 12     | 0            | 0.06     | 80        | 0.24            | 6      |
| Parkinson's disease <sup>77</sup>             | 1940/719 187        | 10-27                   |                        | 0.64 (0.53 to 0.77)   | 6             | 6      | 0            | 0.02     | 29        | ND              | 7      |
| Chronic liver disease <sup>43</sup>           | 1463/437 355        | 6-19                    |                        | 0.62 (0.47 to 0.82)   | 6             | 6      | 0            | 0.07     | 80        | ND              | 6      |
| Liver cirrhosis <sup>63</sup>                 | 1880/130 496        | NP                      |                        | 0.61* (0.45 to 0.84)  | 3             | 3      | 0            | 0        | 0         | ND              | 7      |




NP—not published; NA—not appropriate;  
 ND—not done; NAFLD—non-alcoholic fatty liver disease  
 \*Summary measure expressed as odds ratio in original meta-analysis article  
 †Fixed effects model  
 ‡Could not be separated from other outcomes  
 §Included cross sectional studies

Any vs no coffee consumption

# Café et mortalité





European Prospective Investigation into Cancer and Nutrition (EPIC)  
N=521 330 (10 pays d'EU)

Figure. Subgroup analysis of association between daily coffee consumption and all-cause mortality among men and women.





USA HPFS and NHS  
41 736 H  
86 214 F



# Café-ine et Pression Artérielle

| Source                             | N      | Age, y/Characteristics of Subjects  | Type of Study*                            | Caffeine Dose, mg/d | Effect on Blood Pressure                            |
|------------------------------------|--------|---|---|---------------------|---|
| Robertson et al <sup>6</sup>       | 9      | 21-30/caffeine-naive  | DB, R, P, crossover, acute                | 250                 | Increase  |
| Robertson et al <sup>7</sup>       | 18     | 21-52/caffeine-naive  | DB, R, P, parallel, acute/long-term       | 250                 | Acute, increase; long-term, no change               |
| Ammon et al <sup>8</sup>           | 10     | 20-30/7 d off caffeine  | DB, R, P (DC), crossover, acute/long-term | 504                 | Acute, increase; long-term, no change               |
| Izzo et al <sup>9</sup>            | 20     | 27 ± 1 (n = 12), 62 ± 2 (n = 8)/ caffeine-naive (n = 10), caffeine users (n = 10) | DB, P (n = 8 only), crossover, acute      | 250                 | Caffeine-naive, increase; caffeine users, no change |
| Whitsett et al <sup>10</sup>       | 54     | 22-47/off caffeine 24 h   | Open-label, R, crossover, acute           | 2.2 mg/kg           | Increase  |
| Van Nguyen and Myers <sup>11</sup> | 10     | 24-42/caffeine-naive  | DB, R, P, crossover, acute                | 300                 | Increase  |
| Pincomb et al <sup>12</sup>        | 15     | 20-35/caffeine abstainers   | DB, R, P                                  | 3.3 mg/kg           | Increase  |
| Smits et al <sup>13</sup>          | 8      | 21-25/caffeine users (1-2 d off caffeine)   | Open-label, crossover, acute              | 250-350 (estimated) | Increase  |
| Myers et al <sup>14</sup>          | 70     | 36-75/7 d off caffeine after myocardial infarction                                | DB, R, P, crossover, acute                | 300                 | Increase  |
| Smits et al <sup>15</sup>          | 12     | 17-38/caffeine users  | DB, R, no P, acute                        | 350 (estimated)     | Increase  |
| Lang et al <sup>16</sup>           | 1491   | 15-70/users and abstainers  | Cross-sectional survey, long-term         | ...                 | Increase (diastolic only)                           |
| Lang et al <sup>17</sup>           | 6321   | 18-60/users and abstainers  | Cross-sectional survey, long-term         | ...                 | Increase (systolic only)                            |
| Klatsky et al <sup>18</sup>        | 80 000 | ...   | Cross-sectional survey, long-term         | ...                 | Negatively correlated with caffeine use             |
| Prineas et al <sup>19</sup>        | 7311   | 37-57/male only   | Cross-sectional survey, long-term         | ...                 | Negatively correlated with caffeine use             |
| Periti et al <sup>20</sup>         | 500    | 18-62   | Cross-sectional survey, long-term         | ...                 | Negatively correlated with caffeine use             |
| Charney et al <sup>21</sup>        | 11     | Mean, 37/caffeine users   | Open-label, crossover                     | 10 mg/kg            | No change   |
| Piters et al <sup>25</sup>         | 17     | 40-74/angina patients, caffeine-users   | DB, R, P (DC), crossover, acute           | 100-200 (estimated) | No change   |





# Caféine et pression artérielle: Méta-analyses


| Publication year | Study design included | Number of strata pooled | Number of participants included (% normotensive) | Intervention (caffeine content range) / Exposure | Duration range | Outcome                | Overall associations (95% CI)  |
|------------------|-----------------------|-------------------------|--|--|----------------|------------------------|--|
| 2012             | RCT                   | 10                      | 913 (97%)  | Coffee dose (not reported)                       | 6–16 weeks     | Change in systolic BP  | Coffee dose vs. no coffee dose: -0.55 mmHg (-2.46, 1.36)                 |
|                  |                       |                         |  |  |                | Change in diastolic BP | Coffee dose vs. no coffee dose: -0.45 mmHg (-1.52, 0.61)                 |
| 1999             | RCT                   | 11                      | 522 (96%)  | Coffee dose (504–887 mg)                         | 4–79 days      | Change in systolic BP  | Coffee dose vs. no coffee dose: 2.4 mmHg (1.0, 3.7)                      |
|                  |                       |                         |  |  |                | Change in diastolic BP | Coffee dose vs. no coffee dose: 1.2 mmHg (0.4, 2.1)                      |
| 2005             | RCT                   | 18                      | 1,010 (NS)                                       | Coffee dose (225–798 mg)                         | 9–79 days      | Change in systolic BP  | Coffee dose vs. no coffee or decaffeinated dose: 1.22 mmHg (0.52, 1.92)  |
|                  |                       |                         |  |  |                | Change in diastolic BP | Coffee dose vs. no coffee or decaffeinated dose: 0.49 mmHg (-0.06, 1.04) |
| 2005             | RCT                   | 7                       | 159 (NS)   | Caffeine-only dose (295–750 mg)                  | 7–84 days      | Change in systolic BP  | Caffeine dose vs. no caffeine dose: 4.16 mmHg (2.13, 6.2)                |
|                  |                       |                         |  |  |                | Change in diastolic BP | Caffeine dose vs. no caffeine dose: 2.41 mmHg (0.98, 3.84)               |
| 2012             | Cohort                | 4                       | 1,467,130 (100%)                                 | Self-reported coffee intake                      | 6.4–33 years   | Risk of HTN            | Higher intake vs. lower intake: 1.03 (0.98, 1.08)                        |
| 2011             | Cohort                | 6                       | 172,567 (100%)                                   | Self-reported coffee intake                      | 6.4–33 years   | Risk of HTN            | 1–3 cups/day vs. <1 cup/day: 1.09 (1.01, 1.18)                           |
|                  |                       |                         |  |  |                |                        | 3–5 cups /day vs. <1 cup/day: 1.07 (0.96, 1.20)                          |
|                  |                       |                         |  |  |                |                        | >5 cups /day vs. <1 cup/day: 1.08 (0.96, 1.21)                           |

# Caféine et risque HTA: Méta-analyses


## Risque HTA pour 1 café/J dans études de cohortes




# Caféine: Effets aigus



Caféine iv (250mg):  
 ↑ Activité sympathique  
 ↑ PA, ↑ FC




# Changement PA selon habitudes




Effet de stress mental (MS) sur PA et activité sympathique (MSNA)

# Café chronique et HTA - Singapour



Singapore Health Study:  
n=63'257 chinois 45-74 ans



# Café chronique et HTA - SUN

Seguimiento Universidad Navarra  
N= 13 374 sans HTA Follow-up 9.1 an


Hazard ratios (95% CI) of hypertension according to baseline regular coffee consumption stratified by sex.

|                                | Regular coffee consumption (cups per day) |                  |                  |                  | P for trend |
|--------------------------------|---|------------------|------------------|------------------|-------------|
|                                | Never                                     | <1               | 1                | ≥2               |             |
| <b>Men</b>                     |   |                  |                  |                  |             |
| n                              | 1005                                      | 1048             | 1103             | 1668             |             |
| Person/years                   | 8718                                      | 9284             | 9711             | 15219            |             |
| Crude model                    | 1 Ref.                                    | 1.09 (0.89–1.33) | 1.17 (0.97–1.41) | 1.04 (0.87–1.24) | 0.855       |
| Age, and period adj.           | 1 Ref.                                    | 1.09 (0.90–1.33) | 1.15 (0.96–1.40) | 1.04 (0.87–1.25) | 0.884       |
| Multivariable adj <sup>a</sup> | 1 Ref.                                    | 1.05 (0.86–1.29) | 1.11 (0.92–1.35) | 0.97 (0.81–1.17) | 0.389       |
| <b>Women</b>                   |   |                  |                  |                  |             |
| n                              | 2053                                      | 1552             | 2105             | 2840             |             |
| Person/year                    | 18174                                     | 14148            | 19221            | 26923            |             |
| Crude model                    | 1 Ref.                                    | 0.75 (0.59–0.94) | 0.73 (0.59–0.90) | 0.77 (0.64–0.93) | 0.079       |
| Age, and period adj.           | 1. Ref.                                   | 0.73 (0.58–0.93) | 0.72 (0.59–0.89) | 0.78 (0.65–0.94) | 0.110       |
| Multivariable adj <sup>a</sup> | 1 Ref.                                    | 0.72 (0.57–0.92) | 0.74 (0.60–0.92) | 0.74 (0.61–0.91) | 0.039       |

26% réduction risque HTA seulement chez femmes

# Café chronique et HTA -HAPIEE

Health, Alcohol and Psychosocial factors in Eastern Europe  
N= 2725 sans HTA. Follow-up 5 ans



Consommation de 3-4 café ↓ risque HTA chez non –fumeurs surtout


# Café chronique et HTA -WHIOS

Women Health Initiative Observational Study  
N= 29 985 femme ménauposées sans HTA.

|                          | Intake of caffeinated coffee   |                               |                                    |                                 | <i>P</i> -trend | Intake of decaffeinated coffee   |                               |                                  |                                 | <i>P</i> -trend |
|--------------------------|--------------------------------|-------------------------------|------------------------------------|---------------------------------|-----------------|----------------------------------|-------------------------------|----------------------------------|---------------------------------|-----------------|
|                          | 0 cups/d<br>( <i>n</i> = 6150) | 1 cup/d<br>( <i>n</i> = 6865) | 2–3 cups/d<br>( <i>n</i> = 12,473) | ≥4 cups/d<br>( <i>n</i> = 4497) |                 | 0 cups/d<br>( <i>n</i> = 16,634) | 1 cup/d<br>( <i>n</i> = 6331) | 2–3 cups/d<br>( <i>n</i> = 5555) | ≥4 cups/d<br>( <i>n</i> = 1465) |                 |
| Systolic blood pressure  |                                |                               |                                    |                                 |                 |                                  |                               |                                  |                                 |                 |
| Model 1 <sup>2</sup>     |                                |                               |                                    |                                 |                 |                                  |                               |                                  |                                 |                 |
| Mean                     | 119.8                          | 120.1                         | 120.5                              | 119.9                           | 0.60            | 120.5                            | 119.8                         | 119.8                            | 119.4                           | <0.001          |
| 95% CI                   | (119.5, 120.2)                 | (119.8, 120.5)                | (120.2, 120.7)                     | (119.5, 120.3)                  |                 | (120.3, 120.7)                   | (119.4, 120.1)                | (119.4, 120.2)                   | (118.7, 120.2)                  |                 |
| Model 2 <sup>3</sup>     |                                |                               |                                    |                                 |                 |                                  |                               |                                  |                                 |                 |
| Mean                     | 120.9                          | 120.9                         | 121.2                              | 121.0                           | 0.45            | 121.1                            | 121.0                         | 120.9                            | 120.9                           | 0.06            |
| 95% CI                   | (120.5, 121.4)                 | (120.5, 121.4)                | (120.8, 121.6)                     | (120.5, 121.5)                  |                 | (120.7, 121.5)                   | (120.5, 121.4)                | (120.5, 121.4)                   | (120.1, 121.6)                  |                 |
| Diastolic blood pressure |                                |                               |                                    |                                 |                 |                                  |                               |                                  |                                 |                 |
| Model 1 <sup>2</sup>     |                                |                               |                                    |                                 |                 |                                  |                               |                                  |                                 |                 |
| Mean                     | 71.2                           | 71.6                          | 71.8                               | 71.3                            | 0.40            | 71.8                             | 71.2                          | 71.1                             | 70.9                            | <0.001          |
| 95% CI                   | (71.0, 71.4)                   | (71.4, 71.8)                  | (71.7, 72.0)                       | (71.1, 71.6)                    |                 | (71.7, 71.9)                     | (71.2, 71.6)                  | (71.1, 71.5)                     | (70.6, 71.5)                    |                 |
| Model 2 <sup>3</sup>     |                                |                               |                                    |                                 |                 |                                  |                               |                                  |                                 |                 |
| Mean                     | 71.5                           | 71.8                          | 72.0                               | 71.4                            | 0.13            | 71.9                             | 71.7                          | 71.7                             | 71.5                            | 0.01            |
| 95% CI                   | (71.2, 71.8)                   | (71.6, 72.1)                  | (71.7, 72.2)                       | (71.4, 72.0)                    |                 | (71.7, 72.1)                     | (71.5, 72.0)                  | (71.4, 71.9)                     | (71.1, 72.0)                    |                 |

Légère diminution PAD moy lors de prise décaféiné  
Pas d'augmentation de risque d'HTA


# Caféine / métabolites et pression artérielle



# Métabolites caféine et pression artérielle

| Methylxanthine       | Systolic BP   |                  | Diastolic BP        |              |
|----------------------|---------------|------------------|---------------------|--------------|
|                      | Beta, SE      | PValue           | Beta, SE            | PValue       |
| <b>Caffeine*</b>     |               |                  |                     |              |
| 24 h                 | -0.642, 0.296 | <b>0.030</b>     | 0.252, 0.182        | 0.166        |
| Day                  | -0.505, 0.313 | 0.107            | 0.342, 0.202        | 0.091        |
| Night                | -1.107, 0.315 | <b>&lt;0.001</b> | -0.074, 0.183       | 0.686        |
| <b>Paraxanthine*</b> |               |                  |                     |              |
| 24 h                 | -0.718, 0.343 | <b>0.036</b>     | 0.353, 0.211        | 0.094        |
| Day                  | -0.545, 0.362 | 0.132            | 0.442, 0.234        | 0.059        |
| Night                | -1.376, 0.364 | <b>&lt;0.001</b> | -0.039, 0.212       | 0.851        |
| <b>Theophylline*</b> |               |                  |                     |              |
| 24 h                 | -0.633, 0.341 | 0.064            | 0.391, 0.209        | 0.062        |
| Day                  | -0.458, 0.360 | 0.204            | <b>0.530, 0.232</b> | <b>0.022</b> |
| Night                | -1.183, 0.363 | <b>0.001</b>     | -0.032, 0.211       | 0.881        |
| <b>Theobromine*</b>  |               |                  |                     |              |
| 24 h                 | 0.302, 0.338  | 0.372            | 0.237, 0.208        | 0.254        |
| Day                  | 0.325, 0.357  | 0.363            | 0.263, 0.230        | 0.254        |
| Night                | 0.003, 0.361  | 0.993            | -0.015, 0.209       | 0.942        |

# Effet selon CYP1A2 et tabagisme



A close-up photograph of several dark brown, roasted coffee beans. The beans are arranged in a slightly curved line across the top of the image. The background is dark and out of focus, making the beans stand out. The lighting highlights the texture and creases of the beans.

## Mecanismes potentiels baisse PA

---

- ✓ Effet natriurétique, diurétique
- ✓ Effets sympathomimetiques
- ✓ Relaxation musculaire
- ✓ Inhibition phosphodiesterase
- ✓ Influence sur la rigidité artérielle ?

A close-up photograph of several dark brown, roasted coffee beans. The beans are arranged in a slightly curved line across the top of the image. The lighting is dramatic, highlighting the texture and creases of the beans against a dark, blurred background.


# Mecanismes potentiels baisse PA


---

- ✓ Effet natriurétique, diurétique
- ✓ Effets sympathomimetiques
- ✓ Relaxation musculaire
- ✓ Inhibition phosphodiesterase
- ✓ Influence sur la rigidité artérielle ?

# Effets natriurétiques-diurétiques




Etude randomisée cross-over  
Caféine 250mg po  
8 H volontaires sains






### Caféine chronique atténue HTA liée à sel

- ✓ Augmente excrétion urinaire Na<sup>+</sup>
- ✓ Semble médiée par  $\alpha$ ENaC
- ✓  $\downarrow$  expression Enac médiée par  $\uparrow$  P-AMPK



# Café et rigidité artérielle




Effet aigu sur rigidité artérielle

# Caféine et rigidité artérielle

| Variable                       | Brachial pulse pressure (mm Hg) |                         |                         |                         |  | Pulse wave velocity (m/s) |            |            |                         |  |
|--------------------------------|---------------------------------|-------------------------|-------------------------|-------------------------|--|---------------------------|------------|------------|-------------------------|--|
|                                | Quartile 1<br>(lowest)          | Quartile 2              | Quartile 3              | Quartile 4<br>(highest) | P value for<br>linear trend <sup>b</sup> | Quartile 1<br>(lowest)    | Quartile 2 | Quartile 3 | Quartile 4<br>(highest) | P value for<br>linear trend <sup>b</sup> |
| <b>Caffeine</b>                |                                 |                         |                         |                         |  |                           |            |            |                         |  |
| Age-, sex-,<br>center-adjusted | 43.9 (0.6)                      | 42.5 (0.6)              | 40.9 (0.6) <sup>c</sup> | 40.4 (0.7) <sup>c</sup> | <.001                                    | 8.1 (0.1)                 | 8.1 (0.1)  | 8.0 (0.1)  | 7.7 (0.1) <sup>c</sup>  | .005                                     |
| Model 1                        | 43.6 (0.6)                      | 42.4 (0.6)              | 41.0 (0.6) <sup>c</sup> | 40.7 (0.7) <sup>c</sup> | <.001                                    | 8.1 (0.1)                 | 8.0 (0.1)  | 8.0 (0.1)  | 7.8 (0.1) <sup>c</sup>  | .04                                      |
| Model 2                        | 43.5 (0.5)                      | 42.4 (0.5)              | 41.2 (0.5) <sup>c</sup> | 40.5 (0.6) <sup>c</sup> | <.001                                    | 8.1 (0.1)                 | 8.0 (0.1)  | 8.0 (0.1)  | 7.8 (0.1) <sup>c</sup>  | .03                                      |
| <b>Paraxanthine</b>            |                                 |                         |                         |                         |  |                           |            |            |                         |  |
| Age-, sex-,<br>center-adjusted | 43.8 (0.6)                      | 42.7 (0.6)              | 41.1 (0.6) <sup>c</sup> | 40.2 (0.6) <sup>c</sup> | <.001                                    | 8.1 (0.1)                 | 8.2 (0.1)  | 7.9 (0.1)  | 7.7 (0.1) <sup>c</sup>  | —  |
| Model 1                        | 43.3 (0.6)                      | 42.8 (0.6)              | 41.4 (0.6) <sup>c</sup> | 40.3 (0.6) <sup>c</sup> | <.001                                    | 8.0 (0.1)                 | 8.2 (0.1)  | 7.9 (0.1)  | 7.8 (0.1)               | —  |
| Model 2                        | 43.3 (0.5)                      | 42.9 (0.5)              | 41.3 (0.5) <sup>c</sup> | 40.2 (0.5) <sup>c</sup> | <.001                                    | 8.0 (0.1)                 | 8.2 (0.1)  | 7.9 (0.1)  | 7.8 (0.1)               | —  |
| <b>Theophylline</b>            |                                 |                         |                         |                         |  |                           |            |            |                         |  |
| Age-, sex-,<br>center-adjusted | 43.6 (0.6)                      | 42.7 (0.6)              | 41.3 (0.6) <sup>c</sup> | 40.1 (0.6) <sup>c</sup> | <.001                                    | 8.1 (0.1)                 | 8.1 (0.1)  | 8.0 (0.1)  | 7.7 (0.1) <sup>c</sup>  | —  |
| Model 1                        | 43.1 (0.6)                      | 43.0 (0.6)              | 41.2 (0.6) <sup>c</sup> | 40.4 (0.6) <sup>c</sup> | .001                                     | 8.0 (0.1)                 | 8.1 (0.1)  | 8.0 (0.1)  | 7.8 (0.1) <sup>c</sup>  | —  |
| Model 2                        | 43.1 (0.5)                      | 42.9 (0.5)              | 41.6 (0.5) <sup>c</sup> | 40.1 (0.5) <sup>c</sup> | <.001                                    | 8.0 (0.1)                 | 8.1 (0.1)  | 8.0 (0.1)  | 7.7 (0.1) <sup>c</sup>  | —  |
| <b>Theobromine</b>             |                                 |                         |                         |                         |  |                           |            |            |                         |  |
| Age-, sex-,<br>center-adjusted | 43.1 (0.6)                      | 41.4 (0.6) <sup>c</sup> | 41.2 (0.6) <sup>c</sup> | 42.0 (0.6)              | —  | 8.1 (0.1)                 | 8.0 (0.1)  | 7.9 (0.1)  | 8.0 (0.1)               | —  |
| Model 1                        | 42.8 (0.6)                      | 41.5 (0.6)              | 41.4 (0.6)              | 42.1 (0.6)              | —  | 8.0 (0.1)                 | 7.9 (0.1)  | 7.9 (0.1)  | 8.0 (0.1)               | —  |
| Model 2                        | 42.9 (0.5)                      | 41.5 (0.5) <sup>c</sup> | 41.3 (0.5) <sup>c</sup> | 42.0 (0.5)              | —  | 8.0 (0.1)                 | 7.9 (0.1)  | 7.9 (0.1)  | 8.0 (0.1)               | —  |

# Caféine et Pression Pulsée



# Caféine et Index de résistance rénaux




Figure 2. Relationship of renal resistive index versus number of coffee cups/day.



# CONCLUSIONS

---

- Distinguer effets du café et de la caféine
- Effets différents en aigu et chronique
- Effets différents chez consommateur habitué
- Modification effet par: tabagisme
- Rôle de la génétique et du CYP1A2

# CONCLUSIONS

---

- Effet aigu semble  $\uparrow$  PA
- Effet chronique semble plutôt  $\downarrow$  PA et risque HTA
  - ✓ Liés à natriurèse, diurèse
  - ✓ Effets sur rigidité artérielle
- Effets favorables sur mortalité à confirmer

PAS de recommandations dans Sociétés HTA ?



What else.....

